{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:31:30Z","timestamp":1791577890383,"version":"4.3.4"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4394","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T22:04:31Z","timestamp":1439589871000},"page":"1977-1980","source":"Crossref","is-referenced-by-count":26,"title":["Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors"],"prefix":"10.2169","volume":"54","author":[{"given":"Takaaki","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Futamura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Horiba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Marui","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Gifu Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Gifu Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.","DOI":"10.1093\/jnci\/dji055"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.","DOI":"10.1158\/0008-5472.CAN-04-2818"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mitsudomi T, Morita S, Yatabe Y, et al. West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutaions of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 11: 121-128, 2010.","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zhou C, Wu YI, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2012.","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13: 239-246, 2012.","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 26: 5589-5595, 2008.","DOI":"10.1200\/JCO.2008.16.7254"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 28: 357-360, 2010.","DOI":"10.1200\/JCO.2009.24.7049"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yu HA, Arcilla ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19: 2240-2247, 2013.","DOI":"10.1158\/1078-0432.CCR-12-2246"},{"key":"9","unstructured":"9. Uramoto H, Yamada T, Yano S, et al. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI. Anticancer Res 32: 3785-3790, 2012."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in onco-gene-addicted non-small-cell lung cancer. J Thorac Oncol 7: 1807-1814, 2012.","DOI":"10.1097\/JTO.0b013e3182745948"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Inoue A, Kobayashi K, Maemondo M, et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations [abstract]. J Clin Oncol 29: 7519, 2011.","DOI":"10.1200\/jco.2011.29.15_suppl.7519"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Zhou C, Wu YL, Liu X, et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 30: 7520, 2012.","DOI":"10.1200\/jco.2012.30.15_suppl.7520"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Yu HA, Shima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 8: 346-351, 2013.","DOI":"10.1097\/JTO.0b013e31827e1f83"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Yoshida T, Yoh K, Goto K, et al. Progression patterns at RECIST PD during EGFR-TKIs in advanced NSCLC patients harboring EGFR mutation [abstract]. J Clin Oncol 31: 8078, 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.8078"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Chen MJ, Zhong W, Zhang L, et al. Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib. Chin Med J 126: 2235-2241, 2013.","DOI":"10.3760\/cma.j.issn.0366-6999.20122001"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/16\/54_54.4394\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:12:40Z","timestamp":1718032360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/16\/54_54.4394\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":15,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4394","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}